Abstract: In a method for starting an application, a first device determines a relative location relationship between the first device and a second device; and the first device starts a target application based on the relative location relationship.

Abstract: A method for preventing collisions with static or moving objects in the blind area of a vehicle being driven, applied in an electronic device, includes: obtaining images captured by camera installed on the driven vehicle by implementing a 5G communication method. The images are analyzed for the presence of obstacles. When the images show obstacles, recognizing contours of each obstacle and determining whether the contours of each obstacle is humanoid. When the contours of any obstacle have a human shape, analyzing an extent of the range of the blind area of the vehicle from the images and determining whether an obstacle is within the blind area range of the driven vehicle. If any obstacle is determined to be in the blind area, generating an alarm to the driver of the vehicle by implementing the 5G communication method to activate the alarm device.

Abstract: A method for determining that a terminal device is located inside a geofence includes obtaining, based on a positioning library, a first geographical location corresponding to communication access information of the terminal device. If a location relationship between the first geographical location and the geofence meets a first preset condition, starting a positioning module to obtain a second geographical location of the terminal device and determining, based on the second geographical location, that the terminal device is located inside the geofence.

Abstract: A packing box of a portable device is provided, which includes a main plate body and a frame plate body. Plates, which are adjacent to the main plate body and the frame plate body, are respectively disposed with fold-lines; such that a first side plate of the main plate body overlaps a first bonding plate and a third side plate overlaps a second bonding plate to form an accommodating space.: first frame plate, a second frame plate and a third frame plate of the frame plate body are overlapped with one another, so that the first frame plate, the second fame plate and the third frame plate, which are overlapped with one another, separate the accommodating space through a third bounding plate of the frame plate body. When the main plate body and the frame plate body are flattened, the plates are parallel to one another and flat-shaped.

Abstract: A packing box of a portable device is provided, which includes a main plate body and a frame plate body. Plates, which are adjacent to the main plate body and the frame plate body, are respectively disposed with fold-lines; such that a first side plate of the main plate body overlaps a first bonding plate and a third side plate overlaps a second bonding plate to form an accommodating space.: first frame plate, a second frame plate and a third frame plate of the frame plate body are overlapped with one another, so that the first frame plate, the second fame plate and the third frame plate, which are overlapped with one another, separate the accommodating space through a third bounding plate of the frame plate body. When the main plate body and the frame plate body are flattened, the plates are parallel to one another and flat-shaped.

Abstract: The present invention relates to novel compounds of formula [I] or pharmaceutically acceptable salts thereof: The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

Abstract: The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.

Abstract: The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.

Abstract: The present invention relates to novel compounds of formula [I] or pharmaceutically acceptable salts thereof: The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.

Abstract: The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.

Abstract: The present invention aims to provide novel compounds represented by formula [I] or pharmaceutically acceptable salts thereof: which are useful for prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, convulsion, tremor, pain, or sleep disorders, based on their inhibitory effect against glycine uptake.

Abstract: The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.

Abstract: Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.

Abstract: Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.